Anthropic appointed Vas Narasimhan, former Novartis CEO, to its board as part of a broader push into healthcare, including Claude applications for healthcare and deals with Eli Lilly and Novo Nordisk.

Narasimhan and the LTBT leadership emphasize responsible stewardship of breakthrough science and AI deployment, reinforcing Anthropic’s emphasis on safety and societal impact in its growth trajectory.

For the first time, the LTBT majority now controls the board, signaling a shift in governance dynamics that could influence the balance between stockholders and the company’s public-benefit mission.

There are indications of broader corporate moves, including potential IPO considerations and strategic developments such as hardware partnerships (Google and Broadcom for TPUs) and Claude’s performance benchmarks (SWE-bench, GPQA).

The board move signals a strategic expansion into healthcare, notably drug discovery, with Narasimhan highlighted for contributing to more than 35 novel medicines.

Narasimhan’s arrival intersects with Anthropic’s Long-Term Benefit Trust (LTBT), which serves as an independent oversight body to keep AI development aligned with human benefit and safety.